High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion

Molecular Cancer Therapeutics

Volumn 10, Issue 8, 2011, Pages 1357-1366

  Muinelo Romay, Laura ^a   Colas, Eva ^b   Barbazan, Jorge ^a   Alonso Alconada, Lorena ^a   Alonso Nocelo, Marta ^a   Bouso, Marta ^a   Curiel, Teresa ^a   Cueva, Juan ^a   Anido, Urbano ^a   Forteza, Jeronimo ^a   Gil Moreno, Antonio ^b   Reventos, Jaume ^b   Lopez Lopez, Rafael ^a   Abal, Miguel ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ACTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BIOINFORMATICS; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE INTERACTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INDUSTRIALIZATION; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

BENZAMIDES; CELL LINE, TUMOR; DIOXOLES; ENDOMETRIAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; RECURRENCE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 80051589341     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-1019     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7. (Pubitemid 13194678)
3. Dizon DS. Treatment options for advanced endometrial carcinoma. Gynecol Oncol 2010;117:373-81.
4. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035-41. (Pubitemid 17145924)
5. Abal M, Llaurado M, Doll A, Monge M, Colas E, Gonzalez M, et al. Molecular determinants of invasion in endometrial cancer. Clin Transl Oncol 2007;9:272-7.
6. Delpech Y, Barranger E. Management of lymph nodes in endometrioid uterine cancer. Curr Opin Oncol 2010;22:487-91.
7. Fiorelli JL, Herzog TJ, Wright JD. Current treatment strategies for endometrial cancer. Expert Rev Anticancer Ther 2008;8:1149-57.
8. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36-44. (Pubitemid 46630491)
9. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004;15:1173-8. (Pubitemid 39199303)
10. Kristensen G, Trope C. Endometrial cancer: the management of highrisk disease. Curr Oncol Rep 2004;6:471-5. (Pubitemid 39585693)
11. Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol 2009;36:145-54.
12. Doll A, Gonzalez M, Abal M, Llaurado M, Rigau M, Colas E, et al. An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. Int J Cancer 2009;125:257-63.
13. Colas E, Cabrera-Diaz S, Pedrola N, Monge M, Castelvi J, Eyzaguirre F, et al. Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer.
14. Monge M, Colas E, Doll A, Gonzalez M, Gil-Moreno A, Planaguma J, et al. ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res 2007;67:6753-9. (Pubitemid 47105522)
15. Hennigan RF, Hawker KL, Ozanne BW. Fos-transformation activates genes associated with invasion. Oncogene 1994;9:3591-600. (Pubitemid 24359397)
16. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 2002;45:999-1001. (Pubitemid 34173910)
17. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009;105:107-8.
18. McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106:16-22. (Pubitemid 46898605)
19. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994;127:(6 Pt 2)2021-36.
20. Bergman CA, Talavera F, Christman GM, Baker VV, Roberts JA, Menon KM. Transforming growth factor-beta negatively modulates proliferation and c-fos expression of the human endometrial adenocarcinoma cell line HEC-1-A. Gynecol Oncol 1997;65:63-8. (Pubitemid 27171553)
21. Price JT, Wilson HM, Haites NE. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer 1996; 32:1977-82. (Pubitemid 26361694)
22. Monge M, Doll A, Colas E, Gil-Moreno A, Castellvi J, Garcia A, et al. Subtractive proteomic approach to the endometrial carcinoma invasion front. J Proteome Res 2009;8:4676-84.
23. Monge M, Colas E, Doll A, Gil-Moreno A, Castellvi J, Garcia A, et al. Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis 2009;30:1288-97.
24. Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH, Vissers MC. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res 2010;70:5749-58.
25. Rozanov DV, Savinov AY, Williams R, Liu K, Golubkov VS, Krajewski S, et al. Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res 2008;68:4086-96.
26. Uharcek P. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 2008;34:776-83.
27. Lash GE, Otun HA, Innes BA, Bulmer JN, Searle RF, Robson SC. Inhibition of trophoblast cell invasion by TGFB1, 2, and 3 is associated with a decrease in active proteases. Biol Reprod 2005;73:374-81. (Pubitemid 41022798)
28. Grewal S, Carver JG, Ridley AJ, Mardon HJ. Implantation of the human embryo requires Rac1-dependent endometrial stromal cell migration. Proc Natl Acad Sci U S A 2008;105:16189-94.
29. Bischof P, Campana A. A putative role for oncogenes in trophoblast invasion? Hum Reprod. 2000;15 Suppl 6:51-8. (Pubitemid 32058474)
30. Massague J. TGFbeta in cancer. Cell 2008;134:215-30.
31. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006;17:41-58. (Pubitemid 43117515)
32. Parekh TV, Gama P, Wen X, Demopoulos R, Munger JS, Carcangiu ML, et al. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. Cancer Res 2002;62:2778-90. (Pubitemid 34525761)
33. Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Rechberger T, Jakowicki JA, Krajewska WM. TGF-beta signaling is disrupted in endometrioid- type endometrial carcinomas. Gynecol Oncol 2004;95:173-80. (Pubitemid 39286294)
34. Eritja N, Llobet D, Domingo M, Santacana M, Yeramian A, Matias-Guiu X, et al. A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis. Am J Pathol 2010;176:2722-31.
35. Friedl P, Brocker EB. The biology of cell locomotion within threedimensional extracellular matrix. Cell Mol Life Sci 2000;57:41-64. (Pubitemid 30105329)
36. Wendt MK, Smith JA, Schiemann WP. Transforming growth factorbeta- induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010;29:6485-98.
37. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005;65:5996-6000;discussion-1.
38. Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao M, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26:4319-25.